Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement

Method for Purging Autologous Bone Marrow

Ulla M. Saarinen, Peter Felix Coccia, Nai Kong V. Cheung, Stanton L. Gerson, Robert Pelley

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We describe an in vitro method which is useful for purging autologous bone marrow of neuroblastoma cells. The method utilizes a single murine monoclonal antibody 3G6 (an immunoglobulin Mk) which we have previously developed against the ganglbside G02; undiluted human complement; and unfraction-ated whole bone marrow at 1 x 107 nucleated cells/ml. Tumor cell clonogenic assays, Hoechst 33342 fluorescent nuclear stain, and trypan blue viability stain methods were used to assay cytotoxicity. This complement-mediated cytotoxicity technique killed 99.9-100% of neuroblastoma cell lines NMB-7, LAN-1, LAN-5, and IMR-6, while normal marrow precursor cells were not detectably damaged. The presence of normal bone marrow did not inhibit the human complement-mediated cytotoxicity. Applying the cytotoxicity method to whole unseparated bone marrow demonstrated killing of seeded neuroblastoma cells, with no gross hemolysis or cell clumping. The method did not require expensive special equipment, use of animal complement sera, or prior fractionation of the bone marrow. The average marrow nucleated cell recovery was 95%. These studies indicate that in vitro purging of autologous marrow infiltrated with neuroblastoma with monoclonal antibody 3G6 and human complement is both technically feasible and effective in eradicating residual tumor while preserving bone marrow stem cells.

Original languageEnglish (US)
Pages (from-to)5969-5975
Number of pages7
JournalCancer Research
Volume45
StatePublished - Nov 1 1985

Fingerprint

Bone Marrow Purging
Neuroblastoma
Bone Marrow
Monoclonal Antibodies
Local Area Networks
Bone Marrow Cells
Tumor Stem Cell Assay
Coloring Agents
Trypan Blue
Residual Neoplasm
Hemolysis
In Vitro Techniques
Immunoglobulins
Stem Cells
Cell Line
Equipment and Supplies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Saarinen, U. M., Coccia, P. F., Cheung, N. K. V., Gerson, S. L., & Pelley, R. (1985). Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement: Method for Purging Autologous Bone Marrow. Cancer Research, 45, 5969-5975.

Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement : Method for Purging Autologous Bone Marrow. / Saarinen, Ulla M.; Coccia, Peter Felix; Cheung, Nai Kong V.; Gerson, Stanton L.; Pelley, Robert.

In: Cancer Research, Vol. 45, 01.11.1985, p. 5969-5975.

Research output: Contribution to journalArticle

Saarinen, UM, Coccia, PF, Cheung, NKV, Gerson, SL & Pelley, R 1985, 'Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement: Method for Purging Autologous Bone Marrow', Cancer Research, vol. 45, pp. 5969-5975.
Saarinen, Ulla M. ; Coccia, Peter Felix ; Cheung, Nai Kong V. ; Gerson, Stanton L. ; Pelley, Robert. / Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement : Method for Purging Autologous Bone Marrow. In: Cancer Research. 1985 ; Vol. 45. pp. 5969-5975.
@article{c4d9e233b1ce47eaa9ae0ccc02340582,
title = "Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement: Method for Purging Autologous Bone Marrow",
abstract = "We describe an in vitro method which is useful for purging autologous bone marrow of neuroblastoma cells. The method utilizes a single murine monoclonal antibody 3G6 (an immunoglobulin Mk) which we have previously developed against the ganglbside G02; undiluted human complement; and unfraction-ated whole bone marrow at 1 x 107 nucleated cells/ml. Tumor cell clonogenic assays, Hoechst 33342 fluorescent nuclear stain, and trypan blue viability stain methods were used to assay cytotoxicity. This complement-mediated cytotoxicity technique killed 99.9-100{\%} of neuroblastoma cell lines NMB-7, LAN-1, LAN-5, and IMR-6, while normal marrow precursor cells were not detectably damaged. The presence of normal bone marrow did not inhibit the human complement-mediated cytotoxicity. Applying the cytotoxicity method to whole unseparated bone marrow demonstrated killing of seeded neuroblastoma cells, with no gross hemolysis or cell clumping. The method did not require expensive special equipment, use of animal complement sera, or prior fractionation of the bone marrow. The average marrow nucleated cell recovery was 95{\%}. These studies indicate that in vitro purging of autologous marrow infiltrated with neuroblastoma with monoclonal antibody 3G6 and human complement is both technically feasible and effective in eradicating residual tumor while preserving bone marrow stem cells.",
author = "Saarinen, {Ulla M.} and Coccia, {Peter Felix} and Cheung, {Nai Kong V.} and Gerson, {Stanton L.} and Robert Pelley",
year = "1985",
month = "11",
day = "1",
language = "English (US)",
volume = "45",
pages = "5969--5975",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - Eradication of Neuroblastoma Cells in Vitro by Monoclonal Antibody and Human Complement

T2 - Method for Purging Autologous Bone Marrow

AU - Saarinen, Ulla M.

AU - Coccia, Peter Felix

AU - Cheung, Nai Kong V.

AU - Gerson, Stanton L.

AU - Pelley, Robert

PY - 1985/11/1

Y1 - 1985/11/1

N2 - We describe an in vitro method which is useful for purging autologous bone marrow of neuroblastoma cells. The method utilizes a single murine monoclonal antibody 3G6 (an immunoglobulin Mk) which we have previously developed against the ganglbside G02; undiluted human complement; and unfraction-ated whole bone marrow at 1 x 107 nucleated cells/ml. Tumor cell clonogenic assays, Hoechst 33342 fluorescent nuclear stain, and trypan blue viability stain methods were used to assay cytotoxicity. This complement-mediated cytotoxicity technique killed 99.9-100% of neuroblastoma cell lines NMB-7, LAN-1, LAN-5, and IMR-6, while normal marrow precursor cells were not detectably damaged. The presence of normal bone marrow did not inhibit the human complement-mediated cytotoxicity. Applying the cytotoxicity method to whole unseparated bone marrow demonstrated killing of seeded neuroblastoma cells, with no gross hemolysis or cell clumping. The method did not require expensive special equipment, use of animal complement sera, or prior fractionation of the bone marrow. The average marrow nucleated cell recovery was 95%. These studies indicate that in vitro purging of autologous marrow infiltrated with neuroblastoma with monoclonal antibody 3G6 and human complement is both technically feasible and effective in eradicating residual tumor while preserving bone marrow stem cells.

AB - We describe an in vitro method which is useful for purging autologous bone marrow of neuroblastoma cells. The method utilizes a single murine monoclonal antibody 3G6 (an immunoglobulin Mk) which we have previously developed against the ganglbside G02; undiluted human complement; and unfraction-ated whole bone marrow at 1 x 107 nucleated cells/ml. Tumor cell clonogenic assays, Hoechst 33342 fluorescent nuclear stain, and trypan blue viability stain methods were used to assay cytotoxicity. This complement-mediated cytotoxicity technique killed 99.9-100% of neuroblastoma cell lines NMB-7, LAN-1, LAN-5, and IMR-6, while normal marrow precursor cells were not detectably damaged. The presence of normal bone marrow did not inhibit the human complement-mediated cytotoxicity. Applying the cytotoxicity method to whole unseparated bone marrow demonstrated killing of seeded neuroblastoma cells, with no gross hemolysis or cell clumping. The method did not require expensive special equipment, use of animal complement sera, or prior fractionation of the bone marrow. The average marrow nucleated cell recovery was 95%. These studies indicate that in vitro purging of autologous marrow infiltrated with neuroblastoma with monoclonal antibody 3G6 and human complement is both technically feasible and effective in eradicating residual tumor while preserving bone marrow stem cells.

UR - http://www.scopus.com/inward/record.url?scp=0022399764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022399764&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 5969

EP - 5975

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

ER -